Premaitha Health receives ISO 13485:2003 certification

Achieves significant milestones in preparing for CE-mark and commercial launch

03-Feb-2015 - United Kingdom

Premaitha Health plc  announced that it has met two key requirements for obtaining a CE-mark for its IONA® test: ISO 13485:2003 certification and a successful audit of Annex IV of the In Vitro Diagnostic Medical Device Directive (98/79/EC).

The ISO 13485:2003 certification confirms that Premaitha’s quality management system has been approved as applicable to the design, development and manufacture of in vitro diagnostic reagents and associated software for non-invasive assessment of genetic abnormalities. Certification provides a framework for the award of a CE-mark for Premaitha’s IONA® test, which is now expected in February 2015.

The Company has also been audited against the requirements of Annex IV of the In Vitro Diagnostic Medical Device Directive (98/79/EC) and recommended by the Notified Body, UL International, for a European Commission (EC) certificate demonstrating full quality assurance system approval.  Under the Directive this, in addition to Notified Body review of the technical documentation, will cover the requirements for placing the IONA® test on the European market as an in vitro diagnostic medical device.

Premaitha has made further operational progress in preparation for commercial launch upon award of the CE mark. The Company opened a dedicated, state-of-the art demonstration and training facility for prospects and customers at the end of 2014. Commercial manufacturing has also begun and the Company recently completed the development of a new warehouse facility. Both operations are located at the Company’s headquarters in Manchester, UK.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures